HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prilosec OTC Exceeds Sales Expectations, Drags Down Healthcare Earnings

This article was originally published in The Tan Sheet

Executive Summary

Prilosec OTC sales have been a boon to Procter & Gamble's healthcare top line, but the product's successful launch has negatively impacted earnings a year after its debut

You may also be interested in...

P&G Thinks Globally, Acts Locally With Long-Term Growth Strategy

Procter & Gamble has its eye on broadening its reach in key developing markets as it pursues its comprehensive global growth strategy

Prilosec OTC Sales Top The $400 Mil. Mark; Prevacid Feeling The Burn

Abbott says that Prilosec OTC continues to eat into Prevacid sales and the overall prescription proton pump inhibitor category after one year on the market

People In Brief

Perrigo promotes in pricing, planning


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts